Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Raymond

Showing results (301-310 of 345) with videos related to

Pageof 35
Sort By:
Prostate Cancer and Prostatic Diseases|June 7, 2017
Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validityM E O'Callaghan, E Raymond, J Campbell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Investigational New Drugs|September 18, 1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignanciesH A Burris, E Raymond, A Awada, et al.
Macromolecular Rapid Communications|September 25, 2020
Multifunctional Synthetic Protein Nanoparticles via Reactive ElectrojettingDaniel F Quevedo, Nahal Habibi, Jason V Gregory, et al.
Anti-Cancer Drug Design|January 8, 2000
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryosE Izbicka, D Nishioka, V Marcell, et al.
The American Journal of Cardiology|July 15, 1997
Intravascular ultrasound assessment of the prevalence and causes of angiographic "haziness" following high-pressure coronary stentingK M Ziada, E M Tuzcu, A C De Franco, et al.
Soft Matter|March 20, 2015
Responsive organogels formed by supramolecular self assembly of PEG-<i>block</i>-allyl-functionalized racemic polypeptides into β-sheet-driven polymeric ribbonsJiong Zou, Fuwu Zhang, Yingchao Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 18, 2001
The platelet function dose-response to abciximab during percutaneous coronary revascularization is variableP J Casterella, D J Kereiakes, S R Steinhubl, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 35

Showing results (301-310 of 345) with videos related to

Sort By:
Pageof 35
Prostate Cancer and Prostatic Diseases|June 7, 2017
Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validityM E O'Callaghan, E Raymond, J Campbell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Investigational New Drugs|September 18, 1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignanciesH A Burris, E Raymond, A Awada, et al.
Macromolecular Rapid Communications|September 25, 2020
Multifunctional Synthetic Protein Nanoparticles via Reactive ElectrojettingDaniel F Quevedo, Nahal Habibi, Jason V Gregory, et al.
Anti-Cancer Drug Design|January 8, 2000
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryosE Izbicka, D Nishioka, V Marcell, et al.
The American Journal of Cardiology|July 15, 1997
Intravascular ultrasound assessment of the prevalence and causes of angiographic "haziness" following high-pressure coronary stentingK M Ziada, E M Tuzcu, A C De Franco, et al.
Soft Matter|March 20, 2015
Responsive organogels formed by supramolecular self assembly of PEG-<i>block</i>-allyl-functionalized racemic polypeptides into β-sheet-driven polymeric ribbonsJiong Zou, Fuwu Zhang, Yingchao Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 18, 2001
The platelet function dose-response to abciximab during percutaneous coronary revascularization is variableP J Casterella, D J Kereiakes, S R Steinhubl, et al.
British Journal of Clinical Pharmacology|November 26, 2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)Charlotte van Kesteren, R A A Mathôt, E Raymond, et al.
Pageof 35